Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

Eryn Blass(Dana-Farber Cancer Institute), Patrick A. Ott(Dana-Farber Cancer Institute)

Nature Reviews Clinical Oncology

January 20, 2021

10.1038/s41571-020-00460-2

Cited by 1,006

Related Papers

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

|Science|2018|2.3k

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

|Cell|2018|1.5k

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

|JAMA Oncology|2015|656

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

|Nature Medicine|2021|502

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

|Journal of Thoracic Oncology|2019|437